Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.165 USD | -0.78% | +0.95% | -16.93% |
Apr. 04 | Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug | MT |
Apr. 04 | Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.93% | 192M | |
+1.12% | 42.59B | |
+6.77% | 40.65B | |
+47.47% | 40.57B | |
-11.96% | 26.77B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
+27.16% | 12.05B | |
-3.63% | 11.7B | |
+7.30% | 11.1B |
- Stock Market
- Equities
- ABOS Stock
- News Acumen Pharmaceuticals, Inc.
- Transcript : Acumen Pharmaceuticals, Inc., Q3 2022 Earnings Call, Nov 14, 2022